12:00 AM
Jan 25, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

STI-002: Phase III data

A Chinese Phase III trial in 330 RA patients showed that 3 mg/kg STI-002 plus methotrexate led to an ACR20 response rate of 77%. ACR50 and ACR70 response rates were 50% and 20%, respectively. Additionally,...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >